A Phase 4 interventional study of Sitagliptin phosphate and Placebo in Reactive Hypoglycemia, sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Completed at 1 site in Mexico. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2011-04-26.
Sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Phase 4, Interventional, and Treatment
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.
Symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion. Patients with this abnormality as an early manifestation of glucose intolerance are at higher risk of type 2 diabetes. The pathophysiology of this abnormality appears to be related with delayed first phase insulin release. Improvement of first phase insulin secretion and delay in gastric emptying induced by sitagliptin phosphate could have favorable effects in patients in whom delayed insulin secretion is associated with reactive hypoglycemia.
640 studies on the registry are indexed under Hypoglycemia; 86 are open to participants now.
This study's enrollment of 20 is below the median of 29 across 471 interventional studies indexed under Hypoglycemia.
Browse Hypoglycemia studies →Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran is the lead sponsor of 141 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Sitagliptin phosphate
Drug: Placebo
Sitagliptin phosphate 100 mg per day per 2 weeks
Also known as: Januvia
Placebo 1 tablet per day per 2 weeks
Clinical improvement assessed by a validated questionnaire
Time frame: 2 weeks
Glucose, insulin, GLP1, GIP
Time frame: First and last evaluations
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran